We are live on ! Find out more
PASG icon

Passage Bio

89 hedge funds and large institutions have $786M invested in Passage Bio in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 3

208% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 13

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

25% more funds holding

Funds holding: 7189 (+18)

0.67% more ownership

Funds ownership: 3.51%4.18% (+0.67%)

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

4% less capital invested

Capital invested by funds: $817M → $786M (-$31.2M)

Holders
89
Holders Change
+18
Holders Change %
+25.35%
% of All Funds
1.56%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
21
Increased
40
Reduced
13
Closed
3
Calls
$1K
Puts
$1K
Net Calls
Net Calls Change

PASG Hedge Fund Activity: Q1 2021 in Review

89 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2021, worth a combined $786M — down 3.8% from $817M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PASG positions and 3 closed out — a net gain of 18 holders — while 40 added to existing stakes and 13 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $106M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.25M sold.

  • 89 institutional investors held Passage Bio (PASG) as of Q1 2021, up from 71 in Q4 2020.
  • Funds reported $786M of Passage Bio stock for Q1 2021, down 3.8% quarter-over-quarter.
  • 21 funds opened new Passage Bio positions in Q1 2021 and 3 closed out, a net change of +18 holders.
  • The largest Passage Bio buyer in Q1 2021 was Versant Venture Management, an estimated $106M added.
  • The largest Passage Bio seller in Q1 2021 was RA Capital Management, an estimated $8.25M sold.

Based on aggregated 13F filings for Q1 2021.